Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Status:
Recruiting
Trial end date:
2024-02-20
Target enrollment:
Participant gender:
Summary
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing
chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and
help decrease rate of decreasing donor chimerism and hence decrease relapse without
increasing GVHD